GSK plc:
* GSK PLC - OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS
* GSK - GSK'S OMJJARA (MOMELOTINIB) APPROVED IN JAPAN FOR TREATMENT OF MYELOFIBROSIS Source text for Eikon: Further company coverage:
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,532 GBX | +0.43% | -4.72% | +5.05% |
05:57am | Sembcorp Inks Power Deals with GSK for Singapore Manufacturing Sites; Shares Down 3% | MT |
27/06 | Health Care Stocks Fall With Broad Market -- Health Care Roundup | DJ |
GSK plc:
* GSK PLC - OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS
* GSK - GSK'S OMJJARA (MOMELOTINIB) APPROVED IN JAPAN FOR TREATMENT OF MYELOFIBROSIS Source text for Eikon: Further company coverage:
1st Jan change | Capi. | |
---|---|---|
+5.05% | 78.69B | |
+56.82% | 819B | |
-6.58% | 351B | |
+19.20% | 329B | |
+9.46% | 298B | |
+16.81% | 242B | |
+2.21% | 225B | |
+13.16% | 217B | |
+9.00% | 168B | |
-2.85% | 158B |